A report from the inspector general of HHS examines the latest trends since several biosimilar versions of Humira were ...

On April 14, 2025, Celltrion, Inc. announced that the U.S. Food and Drug Administration granted an interchangeable designation to YUFLYMA (adalimumab-aaty), its biosimilar referencing HUMIRA ...